James B. Yu, MD

James Yu, MD, discusses the validation of the ARCAD nomogram in the real-world setting for patients with stage IV colorectal cancer.

James B. Yu, MD, MHS, discusses the utility of radiation in men with prostate cancer.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses drawbacks of radiation therapy in prostate cancer.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the importance of a genetic counselor in the treatment of patients with prostate cancer.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses emerging standards in radiation for the treatment of patients with prostate cancer.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses radiotherapy versus surgery for patients with prostate cancer.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the significance of the PROTECT study results in prostate cancer.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses moderate hypofractionation replacing the current standard of care for patients with prostate cancer.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses current data in support of using moderate hypofractionation in prostate cancer.

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.